Phase 1 dose-escalation study of safety and tolerability of intravenous CRS-100 in adults with carcinoma and liver metastases.
Phase of Trial: Phase I
Latest Information Update: 07 Feb 2012
At a glance
- Drugs ANZ 100 (Primary)
- Indications Cancer; Cancer metastases
- Focus Adverse reactions
- Sponsors Anza Therapeutics; Cerus Corporation
- 07 Feb 2012 Results were reported in Clinical Cancer Research.
- 26 Apr 2008 Status changed from recruiting to completed.
- 12 Oct 2006 New trial record.